Tesofensine: The Next Weight Loss Peptide?

Key takeaways

Tesofensine is a triple-reuptake inhibitor that blocks the reabsorption of serotonin, dopamine, and noradrenaline in the brain
In a Phase 2 trial of 203 obese adults, the 0.5 mg dose produced 9.2% greater weight loss than placebo over 24 weeks (Astrup et al., 2008) [1]
It works through a completely different mechanism than GLP-1 receptor agonists like semaglutide or tirzepatide
Tesofensine is taken as an oral tablet once daily, which many patients prefer to weekly injections
The drug has not yet completed Phase 3 trials and is not FDA-approved for weight loss
Side effects include increased heart rate, dry mouth, insomnia, and constipation

Tesofensine was originally developed by NeuroSearch as a treatment for Parkinson’s disease and Alzheimer’s disease. During those early trials, researchers noticed something unexpected: patients were losing significant amounts of weight [2].

That observation shifted the drug’s development toward obesity treatment. Tesofensine belongs to a class called triple-reuptake inhibitors (TRIs). It blocks the reabsorption of three neurotransmitters simultaneously: serotonin, dopamine, and noradrenaline. This combination sets it apart from older weight loss drugs that typically targeted only one or two of these pathways [3].

The drug is currently being developed by Saniona (formerly NeuroSearch) under the brand name Tesomet, a fixed-dose combination of tesofensine 0.5 mg with metoprolol 50 mg (a beta-blocker added to offset potential heart rate increases) [4].

How tesofensine works

Most weight loss medications act on the gut or on hormone receptors in the brain. Tesofensine takes a different approach. It targets monoamine neurotransmitter transporters directly.

Here’s what each neurotransmitter contributes:

Serotonin regulates satiety signals. When serotonin stays active longer in the synaptic cleft, you feel full sooner and stay satisfied longer after meals. This is the same pathway that fenfluramine (the “fen” in fen-phen) targeted, though tesofensine acts through a different mechanism [5].

Dopamine controls reward-driven eating. By keeping dopamine active longer, tesofensine appears to reduce the compulsive urge to eat beyond hunger cues. A 2012 rat study found that tesofensine decreased food intake and reduced striatal dopamine D2/D3 receptor availability, which is associated with reduced reward-seeking behavior around food [6].

Noradrenaline (also called norepinephrine) increases energy expenditure. Higher noradrenaline activity boosts metabolic rate and thermogenesis, meaning your body burns more calories at rest [3].

A 2024 study published in PLOS ONE demonstrated that tesofensine silences GABAergic neurons in the hypothalamus, which provides a more detailed picture of how the drug suppresses appetite at the neural circuit level [7].

The combined effect produces weight loss through two paths: reduced calorie intake (you eat less) and increased energy expenditure (you burn more). This dual mechanism may explain why the Phase 2 trial results were stronger than most single-mechanism weight loss drugs [1].

How it compares to GLP-1 medications

If you’ve looked into semaglutide or tirzepatide, you know those drugs work by mimicking gut hormones. They slow gastric emptying, increase insulin secretion, and act on GLP-1 receptors in the brain to reduce appetite.

Tesofensine works entirely differently. It doesn’t affect gut hormones at all. Instead, it modifies how the brain processes reward and satiety signals at the neurotransmitter level [3].

This matters for two reasons. First, patients who don’t respond well to GLP-1 medications may respond to a drug with a different mechanism. Second, the side effect profiles are distinct. GLP-1 drugs commonly cause nausea, vomiting, and diarrhea. Tesofensine’s main side effects are dry mouth, insomnia, and elevated heart rate, with relatively little GI disturbance [1].

Tesofensine is also an oral tablet, unlike injectable peptide therapies. For patients who dislike needles or weekly injections, this is a practical advantage.

Clinical trial results

The Phase 2 PRESTO trial (2008)

The most significant clinical data comes from the Phase 2 randomized, double-blind, placebo-controlled trial published in The Lancet. Astrup and colleagues enrolled 203 obese adults (BMI 30-40) across five Danish obesity centers [1].

Participants were prescribed an energy-restricted diet and randomly assigned to one of four groups for 24 weeks:

Placebo: 2.0% weight loss
Tesofensine 0.25 mg: 4.5% additional weight loss beyond placebo
Tesofensine 0.5 mg: 9.2% additional weight loss beyond placebo
Tesofensine 1.0 mg: 10.6% additional weight loss beyond placebo

The 0.5 mg dose hit the sweet spot between efficacy and tolerability. At that dose, the total weight loss was approximately 11.2% from baseline. The authors concluded that tesofensine 0.5 mg “might have the potential to produce a weight loss twice that of currently approved drugs” at the time [1].

The study completion rate was 79%, which is reasonable for a weight loss trial.

Tesomet in hypothalamic obesity (2022)

A more recent randomized controlled trial tested Tesomet (tesofensine 0.5 mg combined with metoprolol 50 mg) in 21 adults with hypothalamic obesity, a condition notoriously resistant to treatment. After 24 weeks, the Tesomet group lost an additional 6.3% body weight compared to placebo (P = 0.017). Eight of 13 patients on Tesomet achieved at least 5% weight loss, compared to just 1 of 8 on placebo [4].

Importantly, the addition of metoprolol appeared to neutralize the heart rate increases seen in the earlier Phase 2 trial. No significant differences in heart rate or blood pressure were observed between groups [4].

Appetite and satiety effects

A separate analysis of the Phase 2 data found that tesofensine increased composite satiety scores in a dose-dependent manner at week 12, and this satiety increase correlated with weight loss over the full 24 weeks (r = 0.36, P < 0.0001). However, the appetite-suppressing effect appeared to diminish somewhat between weeks 12 and 24 [8].

When participants stopped taking tesofensine, satiety scores returned to baseline levels despite their reduced body weight, suggesting the drug’s appetite effects are pharmacologically driven rather than a result of weight loss itself [8].

Dosing

Based on the Phase 2 data, the 0.5 mg once-daily dose appears to be the target therapeutic dose. This is the dose being carried forward in development [1].

The dosing schedule is straightforward: one oral tablet taken once daily. No reconstitution, no injections, no refrigeration. This simplicity is part of the drug’s appeal.

The Tesomet formulation combines tesofensine 0.5 mg with metoprolol 50 mg in a single tablet, specifically to manage cardiovascular side effects [4].

It’s worth noting that tesofensine is not currently FDA-approved, and it is not available through standard pharmacies or compounding pharmacies. The dosing information here reflects clinical trial protocols, not prescribing recommendations.

Side effects and safety

Tesofensine’s side effect profile differs significantly from GLP-1 drugs. The most common adverse events from the Phase 2 trial included [1]:

Dry mouth
Nausea
Constipation
Hard stools
Diarrhea
Insomnia

The cardiovascular signal is the primary safety concern. At the 0.5 mg dose, heart rate increased by an average of 7.4 beats per minute compared to placebo (P = 0.0001). Blood pressure was not significantly affected at the 0.25 mg or 0.5 mg doses [1].

The 1.0 mg dose showed more pronounced cardiovascular effects, which is why 0.5 mg became the lead dose. The Tesomet formulation addresses the heart rate concern by adding metoprolol, and the hypothalamic obesity trial showed this combination did not produce significant heart rate changes [4].

For a detailed breakdown of adverse events, see our tesofensine side effects page.

Current development status

Tesofensine has had a winding development path. NeuroSearch (now Saniona) completed the Phase 2 trial in 2008 and planned Phase 3 studies, but financial difficulties delayed progress.

As of 2026, Saniona is pursuing development of Tesomet for hypothalamic obesity and Prader-Willi syndrome, two rare conditions with limited treatment options. A Phase 3 trial (TIPO-4) for hypothalamic obesity is in development.

The drug does not have FDA approval for any indication. It is not currently available for prescription in the United States, either as a branded product or through compounding.

Who might benefit from tesofensine

Because tesofensine works through a different pathway than GLP-1 receptor agonists, it could eventually fill a gap for:

Patients who haven’t responded adequately to GLP-1 medications like semaglutide or tirzepatide
People with hypothalamic obesity, where conventional weight loss drugs and lifestyle changes are typically ineffective [4]
Patients who strongly prefer oral tablets over injectable medications
Those who experience intolerable GI side effects from GLP-1 drugs

That said, tesofensine is not currently available for these uses outside of clinical trials. Patients interested in medical weight loss options that are available now should discuss approved therapies with a healthcare provider.

Frequently asked questions

Is tesofensine FDA-approved?▼

No. Tesofensine has not received FDA approval for any indication. It completed a Phase 2 trial for obesity published in The Lancet in 2008 [1] and a small randomized trial for hypothalamic obesity in 2022 [4], but Phase 3 trials for general obesity have not been completed.

How much weight can you lose on tesofensine?▼

In the Phase 2 trial, participants on the 0.5 mg dose lost approximately 11.2% of their body weight over 24 weeks (9.2% more than the placebo group). The 1.0 mg dose produced approximately 12.6% total weight loss, but with more side effects [1]. For context on how this compares, see our tesofensine weight loss data page.

Is tesofensine a peptide?▼

Technically, no. Tesofensine is a small molecule drug, not a peptide. It gets grouped into the weight loss peptide conversation because it’s being explored in the same clinical space as GLP-1 peptides. But its chemical structure and mechanism are entirely different.

Can you buy tesofensine online?▼

Tesofensine is not legally available for purchase in the United States. Any website selling “tesofensine” directly to consumers is selling a research chemical, not a pharmaceutical product. These products are unregulated and their contents are not verified. Learn more about the risks in our guide on research peptides vs prescription.

How does tesofensine compare to phentermine?▼

Both are centrally acting weight loss drugs, but they work differently. Phentermine primarily stimulates noradrenaline release. Tesofensine inhibits the reuptake of serotonin, dopamine, and noradrenaline simultaneously, which produces greater weight loss in clinical trials. Tesofensine 0.5 mg produced approximately 11% weight loss in 24 weeks [1], while phentermine typically produces 5-8% weight loss.

What is Tesomet?▼

Tesomet is a fixed-dose combination of tesofensine 0.5 mg and metoprolol 50 mg developed by Saniona. The metoprolol (a beta-blocker) was added to counteract the heart rate increases observed with tesofensine alone. This combination showed no significant heart rate changes in a clinical trial of hypothalamic obesity patients [4].

Will tesofensine replace GLP-1 drugs?▼

Unlikely. GLP-1 receptor agonists like semaglutide have completed extensive Phase 3 programs and have years of real-world safety data. Tesofensine is far earlier in development. If it eventually gains approval, it would more likely be an alternative option for patients who don’t respond to GLP-1 drugs, not a replacement.

Are there other triple-reuptake inhibitors for weight loss?▼

Tesofensine is the most studied TRI for obesity. A 2025 study in Nature Communications examined the structural basis for how triple-reuptake inhibitors interact with monoamine transporters, which could inform the development of future drugs in this class [9].

References

Astrup A, Madsbad S, Breum L, et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9653):1906-1913. https://pubmed.ncbi.nlm.nih.gov/18950853/
Srivastava G, Apovian C. Future pharmacotherapy for obesity: new anti-obesity drugs on the horizon. Curr Obes Rep. 2018;7(2):147-161. https://pubmed.ncbi.nlm.nih.gov/29504049/
Halford JC, Boyland EJ, Lawton CL, et al. Serotonergic anti-obesity agents: past experience and future prospects. Drugs. 2011;71(17):2247-2255. https://pubmed.ncbi.nlm.nih.gov/22085383/
Huynh K, Klose M, Krogsgaard K, et al. Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity. Eur J Endocrinol. 2022;186(6):687-700. https://pubmed.ncbi.nlm.nih.gov/35294397/
George M, Rajaram M, Shanmugam E. New and emerging drug molecules against obesity. J Cardiovasc Pharmacol Ther. 2014;19(1):65-76. https://pubmed.ncbi.nlm.nih.gov/24064009/
Appel NM, Dunn AJ, Heidbreder C, et al. Triple monoamine inhibitor tesofensine decreases food intake, body weight, and striatal dopamine D2/D3 receptor availability in diet-induced obese rats. Eur Neuropsychopharmacol. 2012;22(4):290-299. https://pubmed.ncbi.nlm.nih.gov/21889317/
Bhatt DK, et al. Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons. PLoS ONE. 2024;19(4):e0301826. https://pubmed.ncbi.nlm.nih.gov/38656972/
Gilbert JA, Gasteyger C, Raben A, et al. The effect of tesofensine on appetite sensations. Obesity. 2012;20(3):553-561. https://pubmed.ncbi.nlm.nih.gov/21720440/
Bhatt DK, et al. Structural basis for pharmacotherapeutic action of triple reuptake inhibitors. Nat Commun. 2025;16(1):123. https://pubmed.ncbi.nlm.nih.gov/41392177/
Heal DJ, Gosden J, Smith SL. Centrally acting agents for obesity: past, present, and future. Drugs. 2018;78(11):1113-1132. https://pubmed.ncbi.nlm.nih.gov/30014268/